🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

102 results for “GlaxoSmithKline Biologicals S.A.” Clear

  1. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline Biologicals S.A.

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  2. Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, Priorix - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze|Masern-Mumps-Röteln

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial

  3. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline Biologicals S.A.

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  4. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  5. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline Biologicals S.A.

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  6. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial

  7. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial

  8. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline Biologicals S.A.

    Varicella

    phase 3 small molecule active

    1 trial

  9. Ventolin 100 microgramos/inhalación suspensión para inhalación en envase a presión* (*) sin CFC

    GlaxoSmithKline Biologicals S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  10. Zelvina 5 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Revlimid 25 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 5 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Revlimid 10 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Zelvina 25 mg hard capsules, DARZALEX 1800 mg solution for injection

    GlaxoSmithKline Biologicals S.A.

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  11. 0.9% Sodium Chloride Injection

    GlaxoSmithKline Biologicals S.A.

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  12. A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

    GlaxoSmithKline Biologicals S.A.

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  13. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline Biologicals S.A.

    Alzheimer's Disease

    phase 2 other active

    1 trial

  14. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  15. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline Biologicals S.A.

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  16. A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

    GlaxoSmithKline Biologicals S.A.

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  17. A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.

    GlaxoSmithKline Biologicals S.A.

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  18. A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

    GlaxoSmithKline Biologicals S.A.

    Multiple Myeloma

    phase 2 other active

    1 trial

  19. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

    GlaxoSmithKline Biologicals S.A.

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  20. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline Biologicals S.A.

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  21. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline Biologicals S.A.

    Influenza, Human

    phase 2 small molecule active

    1 trial

  22. Alpharix suspensie voor injectie in een voorgevulde spuit Trivalent griepvaccin (gefragmenteerd virion, geïnactiveerd)

    GlaxoSmithKline Biologicals S.A.

    Influenza, Human

    phase 2 small molecule active

    1 trial

  23. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline Biologicals S.A.

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  24. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources